Summary
Edwards Lifesciences Corporation (EW) filed an 8-K on January 31, 2019, to report its financial results for the fourth quarter of 2018. The key information is contained within the press release filed as Exhibit 99.1, which details the company's operational and financial performance. Investors should review this press release for specific figures related to revenue, profitability, and any forward-looking statements or guidance provided by the company for upcoming periods. While the 8-K itself is brief, it serves as the official notification that the Q4 2018 earnings release is available. The press release will offer insights into the company's performance in its core business segments, such as transcatheter heart valves and critical care, and potentially address any significant trends or challenges encountered during the quarter. Investors rely on these announcements to assess the company's current financial health and its prospects for future growth.
Key Highlights
- 1Edwards Lifesciences filed an 8-K on January 31, 2019, to announce its Q4 2018 financial results.
- 2The report primarily incorporates by reference a press release dated January 31, 2019 (Exhibit 99.1).
- 3Investors should consult the furnished press release for detailed Q4 2018 financial performance and operational highlights.
- 4The filing serves as an official notification of the release of Q4 2018 earnings.
- 5Information furnished under Item 2.02 is not deemed "filed" for purposes of the Securities Exchange Act of 1934.
- 6The report indicates the event date was January 30, 2019, and it was filed on January 30, 2019, although the press release is dated January 31, 2019.